Form 4: First Wave BioPharma CEO James Sapirstein Sells Shares to Cover Tax Obligations

James Sapirstein, Chairman and CEO of First Wave BioPharma, sold 1,887 shares of common stock on March 15, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• On March 15, 2024, James Sapirstein, the Chairman and CEO of First Wave BioPharma, Inc. (FWBI), sold 1,887 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $4.96, with individual transactions ranging from $4.90 to $5.175.
• Following the transaction, Sapirstein still beneficially owns 37,279 shares, which includes unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations, not necessarily indicative of a positive or negative outlook.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholders due to the small number of shares involved.

Key Dates

Keywords

First Wave BioPharma, FWBI, James Sapirstein, Form 4, SEC, Share Sale, Restricted Stock Units, RSUs, Tax Withholding